University of Antwerp

Diploid hopes to lighten the workload of clinical geneticists drowning in next-generation sequencing data.

Researchers uncovered compound PEX1 or PEX6 mutations in individuals from families affected by a rare condition called Heimler syndrome.

NEW YORK (GenomeWeb) – Researchers affiliated with the University of Antwerp and Antwerp University Hospital have partnered with molecular diagnostics firm Multiplicom to develop a test to help identify individuals at risk for sudden cardiac death.

Aiming to gain a foothold in Europe's emerging next-gen sequencing-based diagnostic market, Multiplicom of Belgium is offering multiplex PCR amplification kits for a range of inherited cancers and other genetic disorders.

Belgian molecular diagnostics firm Multiplicom said this week that it has been awarded €200,000 ($250,000) from the Flemish agency for Innovation by Science and Technology to develop a blood-based non-invasive molecular diagnostic test for fetal aneuploidy.

By Julia Karow
In an effort to unravel the genetics of monogenic forms of epilepsy, a consortium of researchers in Europe has embarked on the Genetics of Rare Epilepsy Syndromes project.

The University of Antwerp spinout's first significant investment will enable it to seek a CE Mark for in vitro diagnostic use of its multiplexed PCR assays for clinical breast cancer and cystic fibrosis sequencing.

CalTech's Peter Bossaerts and colleagues studied whether giving participants equal shares of an invention, and the right to trade them, is better than existing patent models. Bossaerts discussed some of the study's implications for current patent-based economies in a BTW interview.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.